Minor intron retention drives clonal hematopoietic disorders and diverse cancer predisposition
Most eukaryotes harbor two distinct pre-mRNA splicing machineries: the major spliceosome, which removes >99% of introns, and the minor spliceosome, which removes rare, evolutionarily conserved introns. Although hypothesized to serve important regulatory functions, physiologic roles of the minor s...
Saved in:
Published in | Nature genetics Vol. 53; no. 5; pp. 707 - 718 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
New York
Nature Publishing Group US
01.05.2021
Nature Publishing Group |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Most eukaryotes harbor two distinct pre-mRNA splicing machineries: the major spliceosome, which removes >99% of introns, and the minor spliceosome, which removes rare, evolutionarily conserved introns. Although hypothesized to serve important regulatory functions, physiologic roles of the minor spliceosome are not well understood. For example, the minor spliceosome component ZRSR2 is subject to recurrent, leukemia-associated mutations, yet functional connections among minor introns, hematopoiesis and cancers are unclear. Here, we identify that impaired minor intron excision via ZRSR2 loss enhances hematopoietic stem cell self-renewal. CRISPR screens mimicking nonsense-mediated decay of minor intron-containing mRNA species converged on LZTR1, a regulator of RAS-related GTPases.
LZTR1
minor intron retention was also discovered in the RASopathy Noonan syndrome, due to intronic mutations disrupting splicing and diverse solid tumors. These data uncover minor intron recognition as a regulator of hematopoiesis, noncoding mutations within minor introns as potential cancer drivers and links among
ZRSR2
mutations, LZTR1 regulation and leukemias.
Loss of function of the minor spliceosome component ZRSR2 enhances hematopoietic stem cell self-renewal through minor intron retention of its target LZTR1, which is a regulator of RAS-related GTPases. Minor intron retention of LZTR1 was also identified in Noonan syndrome and diverse solid tumor types. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 AUTHOR CONTRIBUTIONS D.I., J.T.P., J.T., R.K.B, and O.A.-W. conceived the project and wrote the paper with editorial contributions from all authors; D.I., J.T., P.C., S.C., S.K., C.F., S.J.H., Y.H., J.M.B.P., E.E.M., C.E., K.K., M.F., H.Y., A.T., C.F., S.X.L., B.H.D, B.L., E.W., S.M., D.Z., R.G., performed experiments; D.I., J.T.P., J.T., A.P., G.-L.C., R.K.B. analyzed data; and F.M., R.K.B., and O.A.-W. supervised the project. |
ISSN: | 1061-4036 1546-1718 1546-1718 |
DOI: | 10.1038/s41588-021-00828-9 |